Literature DB >> 23105652

Tumor marker requests in a general teaching Turkish hospital.

Gülsen Yilmaz1, Fatma Meriç Yilmaz, Mehmet Senes, Dogan Yucel.   

Abstract

Serum tumor markers may be requested inappropriately by clinicians. In this retrospective study, we aimed to investigate the appropriateness of TM requests in our hospital. Patients in the study were identified from the TM requests for 3 months between June-August 2004, using the laboratory database. A total of 2249 patients (1351 men, 898 women) were included in the study and there were 6570 TM requests. The number of requests were 1050 (16%) for Carbohydrate Antigen 19-9, 993 (15.1%) for Cancer Antigen 125, 941 (14.3%) for Prostate Specific Antigen, 921 (14%) for free PSA, 925 (14.1%) for Cancer Antigen 15-3, 788 (12%) for Alphafetoprotein, 730 (11.1%) for Carcinoembryonic Antigen and 222 (3.4%) for AFP/Human Chorionic Gonadotrophin. Our findings support the idea that for the evidence-based use of TM requests the education of clinical staff is required. Clear clinical guidelines including recommendations about the appropriate use of TM can be useful for this education process. Careful audit studies are also useful to determine the impact of these guidelines on the practice of evidence-based laboratory medicine.

Entities:  

Keywords:  Cancer; Evidence-based laboratory medicine; Laboratory management; Tumor markers

Year:  2007        PMID: 23105652      PMCID: PMC3454274          DOI: 10.1007/BF02912881

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  15 in total

Review 1.  Management of the adnexal mass in the 1990s.

Authors:  D G Gallup; E Talledo
Journal:  South Med J       Date:  1997-10       Impact factor: 0.954

2.  The clinical value of tumour markers in the management of ovarian cancer.

Authors:  G J Rustin
Journal:  Ann Clin Biochem       Date:  1996-07       Impact factor: 2.057

3.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.

Authors:  R C Bast; P Ravdin; D F Hayes; S Bates; H Fritsche; J M Jessup; N Kemeny; G Y Locker; R G Mennel; M R Somerfield
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

Review 4.  The clinical utility of the CA 19-9 tumor-associated antigen.

Authors:  W Steinberg
Journal:  Am J Gastroenterol       Date:  1990-04       Impact factor: 10.864

5.  Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.

Authors:  M Mazumdar; D F Bajorin; J Bacik; G Higgins; R J Motzer; G J Bosl
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

Review 6.  Practice guidelines for tumor marker use in the clinic.

Authors:  Catharine Sturgeon
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

7.  Serum alpha-fetoprotein: diagnostic significance in liver disease.

Authors:  E Ruoslahti; M Salaspuro; H Pihko; L Andersson; M Seppälä
Journal:  Br Med J       Date:  1974-06-08

8.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

Authors:  H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

Review 9.  Carcinoembryonic antigen.

Authors:  R H Fletcher
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

Review 10.  Role of the liver in clearance and excretion of circulating carcinoembryonic antigen (CEA).

Authors:  P Thomas; N Zamcheck
Journal:  Dig Dis Sci       Date:  1983-03       Impact factor: 3.199

View more
  1 in total

1.  Tumour markers: An overview.

Authors:  T Malati
Journal:  Indian J Clin Biochem       Date:  2007-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.